+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are studying metabolic dysfunction-associated steatohepatitis MASH in adults to evaluate the effects of two drugs, ECC4703 and ECC0509, alone and combined, on reducing liver fat. This phase 2a trial compares low and high doses of these drugs against placebo to understand their impact on liver fat reduction using MRI scans over 12 weeks. Participants receive oral capsules of ECC4703, ECC0509, their combination, or placebo. The study lasts 12 weeks, during which liver fat content and other related health markers are measured and compared across groups. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants undergo MRI scans, blood tests, and biomarker assessments to monitor liver fat and overall liver health. Measurements include liver enzymes, fibrosis scores, cholesterol, glucose levels, and quality of life questionnaires. Drug levels are also tracked at multiple time points. The trial requires adults aged 18 to 75 with confirmed MASH and stable health to participate.

Age: 18Years - 75YearsAll GendersPhase 2
68 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.

Age: 42Days - 211DaysAll GendersPhase 3
130 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 for adults with excess body weight. This clinical trial compares the study drug against a placebo, both given as weekly injections under the skin, to see how well they help with weight loss. Participants will be randomly assigned to receive one of four doses of NNC0487-0111 or a matching placebo once a week. Both groups will follow a reduced-calorie diet and increase physical activity. The injections are given using pre-filled pen devices on the thigh, abdomen, or upper arm. During the study, participants will have their body weight and other health measures tracked from the start through week 84 and up to week 136. Researchers will monitor waist size, blood pressure, blood sugar levels, cholesterol, and quality of life. Safety will be assessed by counting any side effects through week 140. The total study duration includes treatment and follow-up visits.

Age: 18Years +All GendersPhase 3
72 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of cebranopadol in treating moderate to severe acute pain of surgical or non-surgical origin. This phase 3, open-label, single-arm study focuses on participants aged 18 to 75 years who experience acute pain from ambulatory surgery expected to last at least 72 hours or from traumatic or non-traumatic musculoskeletal conditions. Participants receive cebranopadol at a starting dose of 400 micrograms once daily for up to 14 days or until their pain resolves, whichever comes first. This study does not use a placebo or comparison group, and the treatment is administered openly without masking. During the study, participants will be monitored for pain intensity using the Sum of Pain Intensity Differences through 48 hours SPID48 as the primary outcome measure. They will also be evaluated for safety and tolerability over the treatment period. The study spans from September 2026 to February 2027, with ongoing assessments throughout the treatment duration.

Age: 18Years - 75YearsAll GendersPhase 3
15 locations

1-10 of 15

1